Maxime Dely on a Hopeful Horizon: Promising Advances in Extending Platelet Power
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Platelets don’t sleep: The race to preserve their power longer
This is one of the most strategic questions in transfusion medicine today, as demand rises and logistical constraints tighten.
Platelets are unique cells: living, sensitive, and highly reactive. The moment they leave the human body, they begin a slow deterioration known as the “storage lesion”.
This process alters their metabolism, shape, and aggregation capacity — ultimately impacting their clinical effectiveness.
For a long time, this degradation was considered inevitable. But recent advances are changing the landscape.
Current research highlights several promising pathways:
• Platelet additive solutions (PAS) help reduce spontaneous activation and improve metabolic stability.
• Cold storage, once abandoned, is making a strong comeback thanks to its preservation of hemostatic function.
• Enhanced bag materials, pH control, and optimized agitation help limit the metabolic drift seen over time.
• Monitoring activation markers opens the door to finer, potentially dynamic quality control.
For hospital teams, the impact could be significant: less waste, more flexibility, and better matching between product and patient.
For patients, it means more effective and potentially safer transfusions.
When we look at a platelet concentrate today, we no longer just see a blood product — we see the result of years of research and the early signs of a new generation of transfusion solutions.
What if the next revolution simply came from a better way to preserve what saves lives every day?”
Advance your knowledge with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis